RE:RE:PROMETIC TO REPORT ITS FOURTH QUARTER AND YEAR-END 2016 FINAScott, I would not get your hopes up.
PL has reverted to his prior practices of promising more than he appears able to deliver. He needs to be coached to say less while emphacizing that the company is sticking to its plan.
I think a financing will come prior to the AGM. PLI have been serial issuers in the springtime and I expect 2017 to be no different. The news will be softened with the " allows PLI to retain more of the economics of the product". Of course, we don't know what ownership economics were assumed in PLI's financing outlook anyway. I am growing weary of this form of excuse.
As for a partnership, I am comforted by the fact the Board of Directors created an Asset Monetization Committee to monitor management plans in that regard. I recall from the 2016 Proxy Circular that this Committee met atleast twice in fiscal 2015. It will be interesting to see how active the Committee was in 2016.
The RBC report update comes at a curious time. Why not wait for Q4 numbers seeing as it is only a week away and incorporate managements " official "posturing on Plasminogen approval and related rollout. What does RBC know. What PLI has overlooked, in their approach to public market communication, is having set the street up for mid year timing and " missed", there ought to be a series of " downgrades" by all analysts. Yes its only "delayed by a quarter" but PLI when they issue timelines should " under promise and over deliver". Does not look good if PL is trying to bring more institutional following on board.
I do agree however that 2017 must be a year of execution.
GLTA
Coyote13